ACADIA Pharmaceuticals (NASDAQ: ACAD) had its target price upped by Ladenburg Thalmann from $8.00 to $9.00 in a report released on Wednesday. Ladenburg Thalmann currently has a buy rating on the stock.
ACADIA Pharmaceuticals (NASDAQ: ACAD) traded down 1.25% on Wednesday, hitting $6.31. ACADIA Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $6.88. The stock’s 50-day moving average is currently $6.18. The company’s market cap is $382.5 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cantor Fitzgerald initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Tuesday. They set a buy rating on the stock. Separately, analysts at Cowen initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Monday, January 28th. They set an outperform rating on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Thursday, January 3rd. They set a neutral rating on the stock.
Five equities research analysts have rated the stock with a buy rating, and one has given a hold rating to the company. The company presently has an average rating of buy and a consensus price target of $8.40.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
